These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 9335192)
1. The mobilisation of peripheral blood progenitor cells using chemotherapy, stem cell factor and filgrastim or chemotherapy plus filgrastim alone: a randomised study. Weaver A; Woll PJ; Lind M; Jenkins B; Gill C; Dexter TM; Testa NG; Crother D Sangre (Barc); 1997 Apr; 42 Suppl 1():34. PubMed ID: 9335192 [No Abstract] [Full Text] [Related]
2. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy. Weaver A; Testa NG Bone Marrow Transplant; 1998 Jul; 22(1):33-8. PubMed ID: 9678793 [TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Donato ML; Gershenson D; Ippoliti C; Wharton JT; Bast RC; Aleman A; Anderlini P; Gajewski JG; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin RE Bone Marrow Transplant; 2000 Jun; 25(11):1137-40. PubMed ID: 10849525 [TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
5. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728 [TBL] [Abstract][Full Text] [Related]
6. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. da Silva MG; Pimentel P; Carvalhais A; Barbosa I; Machado A; Campilho F; Sousa SR; Miranda N; da Costa FL; Campos A; Vaz CP; Antas J; Passos-Coelho JL Bone Marrow Transplant; 2004 Oct; 34(8):683-91. PubMed ID: 15322567 [TBL] [Abstract][Full Text] [Related]
7. Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation. Mijovic A; Russell N; Clark RE; Morris TC; Browne P; Crown J; Potter M; Mufti GJ Bone Marrow Transplant; 2005 May; 35(10):1019; author reply 1020. PubMed ID: 15806123 [No Abstract] [Full Text] [Related]
8. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. Fagnoni FF; Lozza L; Zibera C; Zambelli A; Gibelli N; Oliviero B; Ponchio L; Fregoni V; Pavesi L; Perotti C; Da Prada G; Robustelli della Cuna G Bone Marrow Transplant; 2003 Jan; 31(1):31-8. PubMed ID: 12621504 [TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690 [TBL] [Abstract][Full Text] [Related]
11. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264 [TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells. Klein J; Rey P; Dansey R; Karanes C; Abella E; Cassells L; Hamm C; Flowers M; Couwlier C; Peters W; Baynes R Bone Marrow Transplant; 1999 Nov; 24(9):959-63. PubMed ID: 10556954 [TBL] [Abstract][Full Text] [Related]
13. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
14. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501 [TBL] [Abstract][Full Text] [Related]
15. [Monitoring the mobilization of peripheral blood stem cells with G-CSF for allogenic transplantation]. Siles A; Moreno MJ; Ortiz M; Maldonado J Sangre (Barc); 1997 Apr; 42 Suppl 1():27-31. PubMed ID: 9381297 [No Abstract] [Full Text] [Related]
16. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131 [TBL] [Abstract][Full Text] [Related]
17. Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies. Fritsch P; Schwinger W; Schwantzer G; Lackner H; Sovinz P; Wendelin G; Benesch M; Sipurzynski S; Urban C Pediatr Blood Cancer; 2010 Jan; 54(1):134-7. PubMed ID: 19785023 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835 [TBL] [Abstract][Full Text] [Related]
19. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845 [TBL] [Abstract][Full Text] [Related]
20. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]